Patient Selection for Upfront Immunotherapy in NSCLC - O

In this segment, Fred Hirsch, MD, PhD; Suresh Ramalingam, MD; Naiyer Rizvi, MD; and Everett Vokes, MD, discuss trials looking at upfront use of PD-1 inhibitors for metastatic lung adenocarcinoma, consider them in combination with chemotherapy, and provide perspective on patient selection in the context of PD-L1 expression.